BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Recent advances in chemical biology and protein engineering ar
 e expanding the boundaries of which proteins can be modulated pharmacolog
 ically. Multifunctional small molecules (such as molecular glues\, target
 ed protein degraders\, and allosteric modulators) are enabling precise co
 ntrol over protein stability\, localization and activity\, often by explo
 iting endogenous cellular pathways.\n\nIn parallel\, novel biologic modal
 ities\, including engineered antibodies\, multi-specific&nbsp\;binders\, 
 peptide scaffolds\, nucleotide and RNA therapeutics\, offer complementary
  strategies to engage complex or transient target surfaces with high affi
 nity and specificity. Collectively\, these approaches are reshaping early
 ‑stage drug discovery by providing versatile platforms to modulate challe
 nging targets through mechanisms beyond simple inhibition.\n\nFurthermore
 \, hybrid strategies that integrate small molecules with biologics\, such
  as antibody–drug conjugates (ADCs) and chemically enhanced biologics\, a
 re demonstrating synergistic potential. Together\, these emerging technol
 ogies highlight a rapidly evolving therapeutic landscape in which difficu
 lt to drug targets are increasingly accessible\, opening new avenues for 
 disease intervention and precision medicine. Continued innovation in mole
 cular design\, delivery\, and mechanistic understanding will be critical 
 to fully realize the promise of these next‑generation modalities.\n
DTEND:20260617T170000
DTSTAMP:20260512T230902Z
DTSTART:20260616T080000
LOCATION:Pfizer Inc.\, 1\, Portland Street\, Cambridge\, MA\, 02139\,
SEQUENCE:0
SUMMARY:Recent advances in chemical biology and protein engineering are ex
 panding the boundaries of which proteins can be modulated pharmacological
 ly. Mult...
UID:611e44e6-88f0-481a-83a6-f0ce06a1d415
END:VEVENT
END:VCALENDAR